This is one of the biggest peptide regulatory shifts in years. And it's just getting started. The FDA has taken its first step toward reversing its 2023 stance, removing 12 peptides from Regulatory Alert: FDA's April 2026 Update on BPC 157 and GHK Cu Holt Law FDA to Consider Lifting Restrictions on Numerous Compounded Peptides Foley & Lardner BPC 157 and ipamorelin under FDA scrutiny Alex Keoskey posted on the topic LinkedIn